The promise of antiangiogenic therapy for ovarian cancer

Cancer Biology and Therapy

Volumn 8, Issue 23, 2009, Pages 2271-2272

  Jazaeri, Amir A ^a   Slack Davis, Jill K ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Department of Microbiology ^*

Author keywords

Angiogenesis; Bevacizumab; Etaracizumab; LM609; Ovarian cancer; VEGF; v 3 integrin

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; ETARACIZUMAB; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG POTENTIATION; GYNECOLOGIC SURGERY; HUMAN; IN VITRO STUDY; NONHUMAN; NOTE; OVARY CANCER; TREATMENT RESPONSE; TUMOR CELL;

EID: 73949093056     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.23.10414     Document Type: Note

References (13)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
2. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009.
3. Modesitt SC, Jazaeri AA. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin Pharmacother 2007; 8:2293-305.
4. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009; 100:1-7.
5. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25:5180-6.
6. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A gynecologic oncology group study. J Clin Oncol 2007; 25:5165-71.
7. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008; 8:592-603.
8. Hodivala-Dilke K. Alphavbeta3 integrin and angiogenesis: A moody integrin in a changing environment. Curr Opin Cell Biol 2008; 20:514-9.
9. Somanath PR, Ciocea A, Byzova TV. Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem Biophys 2009; 53:53-64.
10. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alphavbeta3 for angiogenesis. Science 1994; 264:569-71.
11. Drake CJ, Cheresh DA, Little CD. An antagonist of integrin alphavbeta3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci 1995; 108:2655-61.
12. Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, et al. Combined anti-angiogenic therapy against VEGF and integrin alpha(V)beta(3) in an orthotopic model of ovarian cancer. Cancer Biol Ther 2009; 8:2250-59.
13. Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt MR, Montag AG, Kistner E, et al. {Beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol 2009.